Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction.
暂无分享,去创建一个
E. Braunwald | C. Cannon | C. McCabe | E. Braunwald | P. Shah | R. Perritt | W. Poole | D. Diver | M. Schweiger | P. Sharis | R. Sequeira | R. Greene | Christopher P. Cannon | Peter J Sharis | Prediman K. Shah | C. Mccabe | Rafael F Sequeira | Rebecca Perritt
[1] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[2] E. Antman. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.
[3] E. Braunwald,et al. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators. , 1995, Journal of the American College of Cardiology.
[4] G. Lamas,et al. Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. , 1995, Circulation.
[5] E. Braunwald,et al. Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group. , 1995, Journal of the American College of Cardiology.
[6] P. Quandalle,et al. Restenosis after delayed coronary angioplasty of the culprit vessel in patients with a recent myocardial infarction treated by thrombolysis. , 1995, Circulation.
[7] C. Cannon,et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. , 1994, Journal of the American College of Cardiology.
[8] G. Lamas,et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. , 1994, Circulation.
[9] C. Cannon,et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. , 1994, Journal of the American College of Cardiology.
[10] E. Braunwald,et al. GUSTO, TIMI and the case for rapid reperfusion. , 1994, Acta cardiologica.
[11] E. Braunwald,et al. Use of composite endpoints in thrombolysis trials of acute myocardial infarction. , 1993, The American journal of cardiology.
[12] P. Kudenchuk,et al. Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (the Myocardial Infarction Triage and Intervention Project). , 1993, The American journal of cardiology.
[13] U. Tebbe,et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. , 1993, Journal of the American College of Cardiology.
[14] S. Hohnloser,et al. Analysis of Creatine Kinase, CK‐MB, Myoglobin, and Troponin T Time‐Activit Curves for Early Assessment of Coronary Artery Reperfusion After Intravenous Thrombolysis , 1993, Circulation.
[15] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[16] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[17] E. Braunwald,et al. An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point. , 1992, Circulation.
[18] H. Hellstrom. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. , 1991, Circulation.
[19] R. Califf,et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. , 1990, Circulation.
[20] David Oakes,et al. Prognostic significance of nonfatal myocardial reinfarction , 1990 .
[21] K. Lee,et al. Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. , 1989, Circulation.
[22] R. Gibbons,et al. Serial quantitative planar technetium-99m isonitrile imaging in acute myocardial infarction: efficacy for noninvasive assessment of thrombolytic therapy. , 1989, Journal of the American College of Cardiology.
[23] E. Braunwald,et al. Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. , 1988, The American journal of cardiology.
[24] A. Jaffe,et al. Myocardial infarct extension: occurrence, outcome, and risk factors in the Multicenter Investigation of Limitation of Infarct Size. , 1988, Annals of internal medicine.
[25] J. Fleiss,et al. Risk stratification and survival after myocardial infarction. , 1983, The New England journal of medicine.